Canakinumab for the treatment of systemic juvenile idiopathic arthritis

Expert Review of Clinical Immunology

Volumn 10, Issue 11, 2014, Pages 1427-1435

  Grom, Alexei A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

anti IL 1b monoclonal antibody; canakinumab; IL 1; systemic juvenile idiopathic arthritis

Indexed keywords

CANAKINUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TOCILIZUMAB; GLUCOCORTICOID; IL1B PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ARTICLE; CLINICAL ASSESSMENT; DEATH; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GASTROENTERITIS; HUMAN; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME; NEUTROPENIA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PHARYNGITIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RHINITIS; RHINOPHARYNGITIS; SINUSITIS; SYSTEMIC DISEASE; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TONSILLITIS; TREATMENT RESPONSE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; ANTAGONISTS AND INHIBITORS; ARTHRITIS, JUVENILE; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ARTHRITIS, JUVENILE; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84911494275     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2014.965149     Document Type: Article

References (42)

1. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet 2011;377: 2138-49
2. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: durban, 1997. J Rheumatol 1998;25:1991-5
3. Still GF. On a form of chronic joint disease in children. Med Chir Trans 1897;80:47-59
4. Schneider R, Laxer RM. Systemic onset juvenile rheumatoid arthritis. Baillieres Clin Rheumatol 1998;12:245-71
5. Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2000;27:491-6
6. Singh-Grewal D, Schneider R, Bayer N, Feldman BM. Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 2006;54:1595-601
7. Lang BA, et al. Radiologic features of systemic onset juvenile rheumatoid arthritis. J Rheumatol 1995;22:168-73
8. Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr 1985;106:561-6
9. Ramanan AV, Schneider R. Macrophage activation syndrome-what's in a name!. J Rheumatol 2003;30:2513-16
10. Grom AA. NK dysfunction: a common pathway in systemic onset juvenile rheumatoid arthritis, macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Arthritis Rheum 2004;50:689-98
11. Filipovich HA. Hemophagocytic lymphohistiocytosis. Immunol Allergy Clin N Am 2002;22:281-300
12. Mellins ED, Macubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011;7:416-26
13. Hull KM, Shoham N, Chae JJ, et al. The expanding spectrum of systemic autoinflammtory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003;15:61-9
14. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86
15. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease J Rheumatol 1998;25: 203-7
16. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40: 1202-9
17. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994;37:1761-9
18. Brunner HI, Lovell DJ, Finck BK, Giannini EH. Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002;29:1058-64
19. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2006; 2(1):28-34
20. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31:2071-5
21. Irigoyen PI, Olson J, Hom C, Ilowite NT. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra. Arthritis Rheum 2004;50(suppl):S437
22. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63:545-55
23. Sandborg C, Mellins ED. A new era in the tretament of systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2439-40
24. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006
25. De Benedetti F, Brunner HI, et al. Tocilizumab in systemic juvenile idiopathic arthritis: a randomized trial. N Engl J Med 2012;367:2385-95
26. Kineret (Anakinra), Highlights of prescribing information. Swedish Orphan Biovitrum AB; Stockholm, Sweden: 2013
27. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54
28. Arcalyst [rilonacept], prescribing information. Tarrytown Regeneron Pharamaceuticals; 2010
29. Lovell DJ, Giannini EH, Reiff AO, et al. Long-term safety and efficacy of Rilonacept in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum 2013;65:2486-96
30. Ilowite NT, Prather K, Lokhnygina Y, et al. The randomized placebo phase study of Rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheum 2014;66(9):2570-9
31. ILARIS, prescribing information. Novartis Pharmaceuticals Corp; East Hanover, NJ, USA: 2013
32. Ruperto N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012;64:557-67
33. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25
34. Kuemmerle-Deschner JB, Ramos E, Blank N, et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther 2011;13:R34
35. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396-406
36. Grom AA, Brunner HI, Ruperto N, et al. Canakinumab is systemic juvenile idiopathic arthritis: impact on the rate and clinical presentation of macrophage activation syndrome. abstr EULAR 2014
37. Brunner HI, Quartier P, Constantin T, et al. Canakinumab in the treatment of systemic juvenile idiopathic arthritis: results from a 12-week pooled post-hoc analysis for efficacy. Arthritis Rheum 2013;65(S10): S112-13
38. Quartier P, Grom AA, Ruperto N, et al. Efficacy of canakinumab in biologic näve versus previously biologic-exposed SJIA patients. Ann Rheum Dis 2014; 73(Suppl 2):Abstract FRI 0528
39. DeWitt EM, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res 2012;64:1001-10
40. Kimura Y, Morgan Dewitt E, Beukelman T, members of the Juvenile Idiopathic Arthritis Disease Specific Research Committee of the Childhood Arthritis and Rheumatology Research Alliance. Adding canakinumab to the childhood arthritis and rheumatology research alliance consensus treatment plans for systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2014;16(9): 1430-1
41. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res 2013;65:1551-63
42. Brachat A, Grom AA, Wulffraat N, et al. Changes in. gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Ann Rheum Dis 2014; 73(Suppl 2):Abstract OP0007